Malaria has plagued humanity for millennia and still exacts a devastating toll, especially on young children across sub-Saharan Africa.
One persistent challenge is adherence: many current regimens demand several carefully timed doses, and incomplete courses can fuel drug resistance.
Scientists at the University of Dundee have pinpointed a drug-like molecule named cabamiquine that may help address this problem.
In early-stage clinical trials conducted in Africa, the compound exhibited an encouraging safety profile among both adults and adolescents.
More significantly, when administered alongside an established partner drug, pyronaridine, it proved effective at suppressing the parasite.
By combining two agents, researchers hope to shorten treatment and reduce the risk that the parasite develops resistance.
A simpler, more forgiving regimen could dramatically improve outcomes in settings where clinics are distant and follow-up is difficult.
The investigators nevertheless stress that these are preliminary findings requiring confirmation in far larger populations.